top of page

Browse by category

Search

AstraZeneca enters obesity market with $2b deal for GLP-1 candidate

AstraZeneca enters obesity market with $2b deal for GLP-1 candidate

AstraZeneca has signed an exclusive license agreement with Shanghai-based biotech Eccogene for ECC5004, an early-stage investigational...

RefluxStop results in 90.9% reduction in GERD-HRQL score

6 hours ago

Journal watch 18/09/2024

1 day ago

Key factors that can impact long-term weight loss in patients with obesity prescribed GLP-1 RA medications

3 days ago

bottom of page